| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
American Journal of Public Health, Vol 90, Issue 10 1562-1569, Copyright © 2000 by American Public Health Association
JOURNAL ARTICLE |
JB Wong, GM McQuillan, JG McHutchison and T Poynard
Department of Medicine, New England Medical Center, Tupper Research Institute, Tufts University School of Medicine, Boston, Mass., USA. jwong@lifespan.org
OBJECTIVES: This study estimated future morbidity, mortality, and costs resulting from hepatitis C virus (HCV). METHODS: We used a computer cohort simulation of the natural history of HCV in the US population. RESULTS: From the year 2010 through 2019, our model projected 165,900 deaths from chronic liver disease, 27,200 deaths from hepatocellular carcinoma, and $10.7 billion in direct medical expenditures for HCV. During this period, HCV may lead to 720,700 years of decompensated cirrhosis and hepatocellular carcinoma and to the loss of 1.83 million years of life in those younger than 65 at a societal cost of $21.3 and $54.2 billion, respectively. In sensitivity analysis, these estimates depended on (1) whether patients with HCV and normal transaminase levels develop progressive liver disease, (2) the extent of alcohol ingestion, and (3) the likelihood of dying from other causes related to the route of HCV acquisition. CONCLUSIONS: Our results confirm prior Centers for Disease Control and Prevention projections and suggest that HCV may lead to a substantial health and economic burden over the next 10 to 20 years.
This article has been cited by other articles:
|
|
 |
|
  A. Rutebemberwa, S. C. Ray, J. Astemborski, J. Levine, L. Liu, K. A. Dowd, S. Clute, C. Wang, A. Korman, A. Sette, et al. High-Programmed Death-1 Levels on Hepatitis C Virus-Specific T Cells during Acute Infection Are Associated with Viral Persistence and Require Preservation of Cognate Antigen during Chronic Infection J. Immunol., December 15, 2008; 181(12): 8215 - 8225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Grow and S. A. Christopher Breaking the Silence Surrounding Hepatitis C by Promoting Self-Efficacy: Hepatitis C Public Service Announcements Qual Health Res, October 1, 2008; 18(10): 1401 - 1412. [Abstract] [PDF]
|
|
|
|
 |
|
 E. M. F. Berkley, K. K. Leslie, S. Arora, C. Qualls, and J. C. Dunkelberg Chronic Hepatitis C in Pregnancy Obstet. Gynecol., August 1, 2008; 112(2): 304 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Li, L. V. Thomassen, A. Majid, B. J. McMahon, D. Bruden, S. McArdle, N. Bano, M. Chung, R. L. Carithers, J. D. Perkins, et al. Investigation of Putative Multisubtype Hepatitis C Virus Infections In Vivo by Heteroduplex Mobility Analysis of Core/Envelope Subgenomes J. Virol., August 1, 2008; 82(15): 7524 - 7532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Brown, W. C. Chapman, R. D. Cook, J. R. Kerr, J. E. Gould, T. K. Pilgram, and M. D. Darcy Chemoembolization of Hepatocellular Carcinoma: Patient Status at Presentation and Outcome over 15 Years at a Single Center Am. J. Roentgenol., March 1, 2008; 190(3): 608 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Sedjo, T. Byers, E. Barrera Jr., C. Cohen, E. T. H. Fontham, L. A. Newman, C. D. Runowicz, A. G. Thorson, M. J. Thun, E. Ward, et al. A Midpoint Assessment of the American Cancer Society Challenge Goal to Decrease Cancer Incidence by 25% Between 1992 and 2015 CA Cancer J Clin, November 1, 2007; 57(6): 326 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Hutton, D. Tan, S. K. So, and M. L. Brandeau Cost-Effectiveness of Screening and Vaccinating Asian and Pacific Islander Adults for Hepatitis B Ann Intern Med, October 2, 2007; 147(7): 460 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Goldman, H. W. Ressom, M. Abdel-Hamid, L. Goldman, A. Wang, R. S. Varghese, Y. An, C. A. Loffredo, S. K. Drake, S. A. Eissa, et al. Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum Carcinogenesis, October 1, 2007; 28(10): 2149 - 2153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-H. Wang, D. M. Netski, J. Astemborski, S. H. Mehta, M. S. Torbenson, D. L. Thomas, and S. C. Ray Progression of Fibrosis during Chronic Hepatitis C Is Associated with Rapid Virus Evolution J. Virol., June 15, 2007; 81(12): 6513 - 6522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Armstrong, A. Wasley, E. P. Simard, G. M. McQuillan, W. L. Kuhnert, and M. J. Alter The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 Ann Intern Med, May 16, 2006; 144(10): 705 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Spaulding, C. M. Weinbaum, D. T.-Y. Lau, R. Sterling, L. B. Seeff, H. S. Margolis, and J. H. Hoofnagle A Framework for Management of Hepatitis C in Prisons Ann Intern Med, May 16, 2006; 144(10): 762 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M.A. Geppert, E. Dettmer, and A. Jakiche Ethical Challenges in the Care of Persons With Hepatitis C Infection: A Pilot Study to Enhance Informed Consent With Veterans Psychosomatics, October 1, 2005; 46(5): 392 - 401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Ferreon, A. C. M. Ferreon, K. Li, and S. M. Lemon Molecular Determinants of TRIF Proteolysis Mediated by the Hepatitis C Virus NS3/4A Protease J. Biol. Chem., May 27, 2005; 280(21): 20483 - 20492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Thomas and A. X. Zhu Hepatocellular Carcinoma: The Need for Progress J. Clin. Oncol., May 1, 2005; 23(13): 2892 - 2899. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Goodman, S. C. Glasgow, M. Schnitzler, J. A. Lowell, S. Shenoy, M. D. Jendrisak, N. Desai, M. Lisker-Melman, J. Crippin, and W. C. Chapman Liver Transplantation for Hepatocellular Carcinoma: Expanding Special Priority to Include Stage III Disease Arch Surg, May 1, 2005; 140(5): 459 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Sherman, S. N. Sherman, T. Chenier, and J. Tsevat Health Values of Patients With Chronic Hepatitis C Infection Arch Intern Med, November 22, 2004; 164(21): 2377 - 2382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Martin What is the current status of liver support devices in the United States? Crit. Care Nurse, August 1, 2004; 24(4): 62 - 64. [Full Text] [PDF]
|
|
|
|
 |
|
 The Global Burden of Hepatitis C Working Group Global Burden of Disease (GBD) for Hepatitis C J. Clin. Pharmacol., January 1, 2004; 44(1): 20 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Instone, T. L. Gilbert, and M. R. Mueller Lessons Learned about Barriers to Hepatitis C Testing: Implications for Policy Policy Politics Nursing Practice, November 1, 2003; 4(4): 288 - 294. [Abstract] [PDF]
|
|
|
|
 |
|
 G. L Armstrong Commentary: Modelling the epidemiology of hepatitis C and its complications Int. J. Epidemiol., October 1, 2003; 32(5): 725 - 726. [Full Text] [PDF]
|
|
|
|
 |
|
 E Giannini, F Botta, P Borro, D Risso, P Romagnoli, A Fasoli, M R Mele, E Testa, C Mansi, V Savarino, et al. Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis Gut, August 1, 2003; 52(8): 1200 - 1205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U Siebert, G Sroczynski, S Rossol, J Wasem, U Ravens-Sieberer, B M Kurth, M P Manns, J G McHutchison, and J B Wong Cost effectiveness of peginterferon {alpha}-2b plus ribavirin versus interferon {alpha}-2b plus ribavirin for initial treatment of chronic hepatitis C Gut, March 1, 2003; 52(3): 425 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Giannini, D. Risso, F. Botta, B. Chiarbonello, A. Fasoli, F. Malfatti, P. Romagnoli, E. Testa, P. Ceppa, and R. Testa Validity and Clinical Utility of the Aspartate Aminotransferase-Alanine Aminotransferase Ratio in Assessing Disease Severity and Prognosis in Patients With Hepatitis C Virus-Related Chronic Liver Disease Arch Intern Med, January 27, 2003; 163(2): 218 - 224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. C. Kuehne, U. Bethe, K. Freedberg, and S. J. Goldie Treatment for Hepatitis C Virus in Human Immunodeficiency Virus-Infected Patients: Clinical Benefits and Cost-effectiveness Arch Intern Med, December 9, 2002; 162(22): 2545 - 2556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Salomon, M. C. Weinstein, J. K. Hammitt, and S. J. Goldie Empirically Calibrated Model of Hepatitis C Virus Infection in the United States Am. J. Epidemiol., October 15, 2002; 156(8): 761 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L Davis Treatment of chronic hepatitis C BMJ, November 17, 2001; 323(7322): 1141 - 1142. [Full Text] [PDF]
|
|
|
|
|
|
J. P. Leigh, C. L. Bowlus, B. N. Leistikow, and M. Schenker Costs of Hepatitis C Arch Intern Med, October 8, 2001; 161(18): 2231 - 2237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Davis and J. R. Rodrigue Treatment of Chronic Hepatitis C in Active Drug Users N. Engl. J. Med., July 19, 2001; 345(3): 215 - 217. [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Howe, P. A. Wingo, M. J. Thun, L. A. G. Ries, H. M. Rosenberg, E. G. Feigal, and B. K. Edwards Annual Report to the Nation on the Status of Cancer (1973 Through 1998), Featuring Cancers With Recent Increasing Trends J Natl Cancer Inst, June 6, 2001; 93(11): 824 - 842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Koff Nonresponse to Interferon in Chronic Hepatitis C: Re-treatment Redux JAMA, January 10, 2001; 285(2): 212 - 214. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
